ReviewThe Journal of clinical endocrinology and metabolism2025
Genotype-Phenotype Correlations in the Hyperparathyroidism-Jaw Tumor Syndrome.
Review in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Parathyroid Carcinoma: From Molecular Pathogenesis and Diagnostic Biomarkers to Targeted Therapeutics.International journal of molecular sciences · 2026Review
- Article
- An Analysis of Primary Hyperparathyroidism in Individuals Diagnosed with Multiple Endocrine Neoplasia Type 2.Diseases (Basel, Switzerland) · 2025Review
- Heritable hyperparathyroidism: Genetic insights and clinical implications.Best practice & research. Clinical endocrinology & metabolism · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Establishing genotype-phenotype correlations in disorders of hereditary endocrine neoplasia is important for clinical screening, genetic counseling, prognostication, surveillance, and surgical strategy, and may also provide clues about disease pathogenesis. Important genotype-phenotype correlations are recognized, for example, in pheochromocytoma/paraganglioma and multiple endocrine neoplasia type 2A. The presence of such correlations has been less clear in other familial endocrine disorders associated with primary hyperparathyroidism including multiple endocrine neoplasia type 1, and the hyperparathyroidism-jaw tumor syndrome (HPT-JT). Characteristic features of HPT-JT, apart from fibro-osseous jaw tumors and uterine lesions, include renal neoplasms, such as Wilms tumor and mixed epithelial and stromal tumor ("renal hamartomas"), and a high incidence of parathyroid cancer. Emerging evidence suggests two different genotype-phenotype correlations in HPT-JT based on the type of variant in the CDC73 tumor suppressor gene. Although multiple CDC73 genotypes can give rise to the Wilms tumor phenotype in HPT-JT, the development of mixed epithelial and stromal tumor of the kidney specifically correlates with the presence of a start-loss variant affecting the initiator methionine codon of parafibromin, the protein product encoded by CDC73. Furthermore, the risk of parathyroid cancer in HPT-JT also appears to correlate with genotype: CDC73 frameshift indel, splice-site, and stop-gain genotypes are associated with a greatly increased risk of parathyroid carcinoma compared to carriers of CDC73 missense and nonframeshift indel variants. The recognition of such genotype-phenotype correlations in HPT-JT may impact genetic counseling, patient care and disease surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.